Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan

Cheng, Kuang Fu; Liao, Kuan‐Fu; Lin, Cheng‐Li; Lai, Shih‐Wei

doi:10.3389/fphar.2017.00481

Cited by 30 publications

(17 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All comorbidities were diagnosed based on ICD-9 codes. The accuracy of ICD-9 codes has been well discussed in previous studies (Shen et al, 2016 ; Cheng et al, 2017 ; Lai et al, 2017d ; Liao et al, 2017a , c ). To increase the diagnosis validity, subjects who had the same diagnosis for three consecutive clinical visits in the ambulatory care and/or one episode of hospitalization diagnosis during the study period were included.…”

Section: Methodsmentioning

confidence: 75%

Population-Based Case-Control Study Assessing the Association between Statins Use and Pulmonary Tuberculosis in Taiwan

2017

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Little evidence is available about the relationship between statins use and pulmonary tuberculosis in Taiwan. The aim of the study was to explore this issue.Methods: Using the database of the Taiwan National Health Insurance Program, we conducted a population-based case-control study to identify 8,236 subjects aged 20 years and older with newly diagnosed pulmonary tuberculosis from 2000 to 2013 as the cases. We randomly selected 8,236 sex-matched and age-matched subjects without pulmonary tuberculosis as the controls. Subjects who had at least one prescription of statins before the index date were defined as “ever use.” Subjects who never had one prescription of statins before the index date were defined as “never use.” The odds ratio (OR) and 95% confidence interval (CI) for pulmonary tuberculosis associated with statins use was estimated by a multivariable logistic regression model.Results: After adjustment for co-variables, the adjusted OR of pulmonary tuberculosis was 0.67 for subjects with ever use of statins (95% CI 0.59, 0.75). In a sub-analysis, the adjusted ORs of pulmonary tuberculosis were 0.87 (95% CI 0.69, 1.10) for subjects with cumulative duration of statins use <3 months, 0.77 (95% CI 0.58, 1.03) for 3–6 months, and 0.59 (95% CI 0.51, 0.68) for ≥6 months, compared with subjects with never use of statins.Conclusions: Statins use correlates with a small but statistically significant risk reduction of pulmonary tuberculosis. The protective effect is stronger for longer duration of statins use. Due to a case-control design, a causal-relationship cannot be established in our study. A prospective cohort design is needed to confirm our findings.

show abstract

Section: Methodsmentioning

confidence: 75%

Population-Based Case-Control Study Assessing the Association between Statins Use and Pulmonary Tuberculosis in Taiwan

2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, only subjects whose cumulative duration of zolpidem use was ≥12 months were included. The definition of medication exposure was adapted from previous studies ( Cheng et al, 2017 ; Lai et al, 2017 ; Liao et al, 2017c , d ). Subjects who did not have a prescription for medications studied were classified as never use.…”

Section: Methodsmentioning

confidence: 99%

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

2017

Self Cite

View full text Add to dashboard Cite

Background/Objectives: Previous studies showed that zolpidem use could be associated with increased cancer risk, but the role of zolpidem on hepatocellular carcinoma (HCC) risk remains undetermined. The study purpose was to examine the association between HCC risk and zolpidem use in Taiwan.Methods: Using the database from the Taiwan National Health Insurance Program, we designed a case-control study which consisted of 77986 subjects aged 20 years or older with newly diagnosed HCC as the case group, and 77986 subjects without HCC as the control group, from 2000 to 2011. Ever use of zolpidem was defined as a subject who had at least a prescription for zolpidem before the index date. Never use was defined as a subject who did not have a prescription for zolpidem before the index date. The association between HCC risk and zolpidem use was determined by the odds ratio (OR) and 95% confidence interval (CI) in a multivariable logistic regression model.Results: After adjustment for confounding factors, the adjusted OR of HCC was 1.05 (95% CI 0.97, 1.13) for subjects with ever use of zolpidem, compared with never use of zolpidem. The adjusted OR of HCC was 1.01 for subjects with increasing cumulative duration of zolpidem use for every 1 year (95% CI 0.99, 1.03), compared with never use of zolpidem.Conclusion: There is no significant association between HCC risk and zolpidem use. There is no duration-dependent effect of zolpidem use on HCC risk.

show abstract

“…Proton pump inhibitors therapy has been found to be associated with some comorbidities 1. Recently, one case-control study disclosed a positive association between tuberculosis and proton pump inhibitors therapy (OR=1.13; 95% CI 1.10 to 1.28),2 which was compatible with another case-control study in Taiwan (OR=1.31; 95% CI 1.22 to 1.41) 3. Some points need to be discussed.…”

mentioning

confidence: 56%

Association between pulmonary tuberculosis and acid suppressive agents

Lai

Lin

Liao

2019

Postgraduate Medical Journal

Self Cite

View full text Add to dashboard Cite

Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan

Cited by 30 publications

References 53 publications

Population-Based Case-Control Study Assessing the Association between Statins Use and Pulmonary Tuberculosis in Taiwan

Population-Based Case-Control Study Assessing the Association between Statins Use and Pulmonary Tuberculosis in Taiwan

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

Association between pulmonary tuberculosis and acid suppressive agents

Contact Info

Product

Resources

About